Research and Development Expenses

What are Research and Development Expenses?

Research and Development Expenses (R&D Expenses) are the costs a company incurs to invent, design, test, and improve products, services, and processes. On the income statement they sit inside operating expenses, between gross profit and operating income, and they directly reduce reported earnings in the period they are incurred (with limited exceptions covered below).

Typical R&D line items include:

• Personnel: salaries, benefits, and stock-based compensation for scientists, engineers, and technical staff.
• Materials and supplies: prototypes, reagents, components, and testing rigs consumed during development.
• Equipment and facilities: depreciation, rent, and maintenance of laboratories and pilot plants.
• Outside services: contract research organizations (CROs), consultants, software licenses, and royalties for licensed technology.
• Capitalized software: under US GAAP ASC 985-20 (software for sale) and ASC 350-40 (internal-use software), select development-phase costs are capitalized as intangible assets and amortized.

Why are R&D Expenses important?

R&D drives the long-run growth rate. Companies that consistently spend more than peers on R&D — and convert that spend into new products — compound value faster than the market expects, which is why R&D-heavy issuers like NVDA, GOOGL, and LLY often trade at premium multiples even when current EPS looks expensive.

For investors, three lenses matter:

1. Earnings quality. Because R&D is expensed (not capitalized), high-R&D companies under-report economic earnings under GAAP. Aswath Damodaran's R&D-capitalization framework adds back R&D, amortizes it over the useful life, and produces a corrected earnings number that often shifts P/E meaningfully.
2. Reinvestment runway. R&D-to-revenue measures the share of every dollar a company reinvests into the future. The right benchmark is sector-specific — see the table below.
3. Operating leverage. When R&D scales sublinearly with revenue (e.g., a software platform), each incremental dollar of revenue drops more to operating income, expanding margins.

How are R&D Expenses calculated?

R&D Expenses are reported as the sum of all costs directly attributable to development activity in the period:

$$\textsf{R\&D Expenses} = \textsf{Personnel} + \textsf{Materials} + \textsf{Equipment \& Facilities} + \textsf{Contracted R\&D} - \textsf{Capitalized Development Cost}$$

Companies disclose the gross R&D expense in the income statement and additional detail (R&D headcount, capitalized vs. expensed split, geography of R&D) in the 10-K. Always cross-check the cash flow statement: the share-based compensation line tells you how much of the reported R&D is non-cash.

What is the R&D-to-revenue ratio?

The R&D-to-revenue (or R&D intensity) ratio normalizes R&D spend by company size. It is the simplest comparator across peers.

$$\textsf{R\&D Intensity} = \frac{\textsf{R\&D Expenses}}{\textsf{Total Revenue}}$$

What "healthy" looks like depends on the sector:

How does R&D affect EPS?

Because R&D is expensed in the year incurred, a company that doubles R&D spend in a single year will see operating income drop by the incremental spend, mechanically lowering EPS. This is why management often telegraphs R&D ramps — the market accepts a near-term EPS hit if it sees a credible product roadmap.

The opposite is also true: R&D is a discretionary line item that can be flexed to defend EPS. If a company is consistently growing revenue but flat-lining or shrinking R&D, that is a yellow flag — the management may be borrowing future growth to hit a quarterly number.

Is R&D capitalised under GAAP and IFRS?

US GAAP (ASC 730) — default: expense as incurred. Most R&D is expensed in the period. Two exceptions:

1. Software development cost post-technological feasibility (ASC 985-20) and internal-use software in the application development stage (ASC 350-40).
2. Acquired in-process R&D (IPR&D) from a business combination, which is recognized as an indefinite-lived intangible until completion or abandonment.

IFRS (IAS 38) — bifurcated. "Research" costs are expensed; "development" costs are capitalized once the company can demonstrate technical feasibility, intent and ability to complete, future economic benefits, and reliable cost measurement. The result: IFRS filers often report higher reported assets and EBITDA than otherwise-comparable US GAAP filers.

Investors comparing cross-jurisdiction peers should normalize: either capitalize R&D for the GAAP filer, or expense capitalized development cost for the IFRS filer.

What are common R&D tax credits and incentives?

• United States — Section 41 R&D Credit. A federal credit equal to 14–20 % of qualifying research expenditures over a base amount. The 2017 TCJA introduced mandatory amortization of R&D under IRC §174 (5 years domestic, 15 years foreign) starting tax year 2022, which lifted reported cash taxes for many R&D-heavy companies.
• United Kingdom — RDEC. The Research and Development Expenditure Credit provides an above-the-line credit (currently 20 %) for qualifying R&D, reducing both the tax bill and the effective cost of R&D headcount.
• EU — Patent Box / IP Box regimes. Multiple member states tax IP-derived income at preferential rates, indirectly subsidizing the R&D that generates the IP.

What investors should watch

• Sudden R&D cuts. If R&D growth materially decelerates while revenue grows, ask why — often a pre-IPO/pre-deal earnings management signal.
• R&D efficiency. Track revenue per R&D dollar (1/intensity). Persistent decline = compounding execution problem.
• Capitalized R&D ratio. If a company aggressively capitalizes (under either ASC 985 or IAS 38), reported R&D understates the cash outflow. Reconcile against the cash flow statement.
• Stock-based comp share of R&D. Heavy SBC inside R&D inflates non-cash expense and flatters reported FCF — adjust SBC out of FCF to get a comparable cash R&D number.

Related concepts on BearBull

• Operating expenses
• Operating income
• Selling, general & administrative expenses
• Net income

Additional considerations

• Capitalization vs. expense: Some development costs may be capitalized as intangible assets, affecting the income statement in a different period than the cash outlay.
• R&D intensity by stage of company: Early-stage companies (pre-product-market fit) often run R&D >50 % of revenue; that is not a margin problem, that is the business model.
• Tax incentives: R&D credits and grants offset the cost; always read the tax-rate reconciliation footnote to size the benefit.